Cargando…
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Significant progress has been made in the advancement of RNAi therapeutics by combining a synthetic triantennary N-acetylgalactosamine ligand targeting the asialoglycoprotein receptor with chemically modified small interfering RNA (siRNA) designs, including the recently described Enhanced Stabilizat...
Autores principales: | Foster, Donald J., Brown, Christopher R., Shaikh, Sarfraz, Trapp, Casey, Schlegel, Mark K., Qian, Kun, Sehgal, Alfica, Rajeev, Kallanthottathil G., Jadhav, Vasant, Manoharan, Muthiah, Kuchimanchi, Satya, Maier, Martin A., Milstein, Stuart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910670/ https://www.ncbi.nlm.nih.gov/pubmed/29456020 http://dx.doi.org/10.1016/j.ymthe.2017.12.021 |
Ejemplares similares
-
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017) -
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020) -
Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
por: Willoughby, Jennifer L.S., et al.
Publicado: (2018) -
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
por: Janas, Maja M., et al.
Publicado: (2018) -
Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
por: Janas, Maja M, et al.
Publicado: (2019)